Ryohei Katayama

Principal Investigator / Chief

Cancer Institute Hospital of Japanese Foundation for Cancer Research

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ryohei Katayama is a Principal Investigator and Chief at the Japanese Foundation For Cancer Research in Japan. His research focuses on the mechanisms of drug resistance in various cancers, particularly non-small cell lung cancer and colorectal cancer. Recent articles by Dr. Katayama explore topics such as the synergy between apoptosis and ER stress in glioblastoma, AXL-mediated drug resistance, and the development of drug-tolerant persister cells in ALK-positive lung cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (2)

Narumi Sakaguchi

Chugai Pharmaceutical

JAPAN

View details

Shigeki Yoshiura

Chugai Pharmaceutical

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ryohei Katayama

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma

AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer

Identification of C-mannosylation in a receptor tyrosine kinase AXL

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer

ID3 is a novel target gene of p53 and modulates lung cancer cell metastasis

BET protein–dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer

Collaborators (2)

Narumi Sakaguchi

Shigeki Yoshiura

Make your next move.